Skip to main content
    C

    CytomX Therapeutics Inc (CTMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.99
    -0.06 (-2.70%)

    Market Cap: $444.73M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CytomX Therapeutics Inc (CTMX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    CytomX Therapeutics (CTMX) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, CytomX Therapeutics reported EPS of -$0.09, below the -$0.07 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    +31.09%

    Upcoming Estimates

    Reports Mar 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.10
    Range-$0.12 - -$0.06
    10 analysts
    Revenue Consensus
    $5.75M
    Range$1.96M - $10.50M
    8 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.10
    Range-$0.13 - -$0.05
    5 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.13+21.8%
    60d ago-$0.13+21.8%
    30d ago-$0.13+21.8%
    7d ago-$0.13+21.8%
    Current-$0.10
    Revenue Consensus
    $5.08M
    RangeN/A
    4 analysts

    Next Report

    CTMX has an expected report date of Mar 15, 2027.

    CTMX Earnings Call

    The latest CTMX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, CTMX beat 23 and missed 16. Revenue for the quarter ended Sep 30, 2026 was $1.69M, down 71.6% from $5.96M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.09-$0.07-$0.11 - $0.03-28.57%MissN/A74 up, 1 downNov 5, 2026$1.69M
    Jun 30, 2026-$0.09-$0.11-$0.13 - -$0.09+18.18%BeatN/A62 up, 4 downAug 6, 2026$1.42M
    Mar 31, 2026-$0.10-$0.11-$0.16 - -$0.08+9.09%Beat-137.0%82 up, 2 downMay 7, 2026$10.26M
    Dec 31, 2025-$0.22-$0.09-$0.17 - -$0.03-134.79%Miss-195.7%80 up, 4 downMar 16, 2026$663000
    Sep 30, 2025-$0.09-$0.04-$0.09 - $0.00-125.00%Miss-228.6%71 up, 0 downNov 6, 2025$5.96M
    Jun 30, 2025$0.00-$0.06-$0.12 - $0.02+98.00%BeatN/A60 up, 5 downAug 7, 2025$18.66M
    Mar 31, 2025$0.27$0.13-$0.08 - $0.25+104.24%Beat+58.8%51 up, 0 downMay 12, 2025$50.92M
    Dec 31, 2024$0.23-$0.11-$0.16 - -$0.01+309.09%Beat+2200.0%41 up, 0 downMar 6, 2025$38.09M
    Sep 30, 2024$0.07-$0.13-$0.28 - -$0.09+153.85%Beat+75.0%70 up, 0 downNov 7, 2024$33.43M
    Jun 30, 2024-$0.08-$0.06-$0.25 - -$0.01-33.33%MissN/A60 up, 0 downAug 8, 2024$25.11M
    Mar 31, 2024$0.17-$0.06-$0.22 - $0.02+383.33%BeatN/A60 up, 1 downMay 8, 2024$41.46M
    Dec 31, 2023$0.01-$0.03-$0.24 - $0.12+133.33%BeatN/A70 up, 0 downMar 11, 2024$26.61M
    Sep 30, 2023$0.04-$0.21-$0.41 - -$0.05+119.05%BeatN/A90 up, 0 downNov 7, 2023$26.38M
    Jun 30, 2023-$0.02-$0.20-$0.39 - -$0.13+90.00%BeatN/A80 up, 0 downAug 8, 2023$24.72M
    Mar 31, 2023-$0.05-$0.11-$0.33 - $0.14+54.55%BeatN/A82 up, 1 downMay 9, 2023$23.50M
    Dec 31, 2022-$0.43-$0.24-$0.44 - -$0.14-79.17%MissN/A90 up, 0 downMar 27, 2023$20.12M
    Sep 30, 2022-$0.35-$0.33-$0.44 - -$0.19-6.06%MissN/A90 up, 0 downNov 8, 2022$11.15M
    Jun 30, 2022-$0.37-$0.40-$0.51 - -$0.18+7.50%BeatN/A91 up, 0 downAug 4, 2022$12.85M
    Mar 31, 2022-$0.37-$0.36-$0.44 - -$0.26-2.78%MissN/A90 up, 0 downMay 5, 2022$9.04M
    Dec 31, 2021-$0.40-$0.28-$0.40 - $0.23-42.86%MissN/A9N/AMar 1, 2022N/A
    Sep 30, 2021-$0.35-$0.30-$0.43 - -$0.16-16.67%MissN/A8N/ANov 4, 2021$17.59M
    Jun 30, 2021-$0.30-$0.31-$0.52 - -$0.16+3.23%BeatN/A11N/AAug 5, 2021$16.29M
    Mar 31, 2021-$0.26-$0.35-$0.52 - -$0.06+25.71%Beat-200.0%11N/AMay 6, 2021$15.97M
    Dec 31, 2020-$0.32-$0.50-$1.16 - -$0.32+36.00%BeatN/A10N/AFeb 24, 2021N/A
    Sep 30, 2020-$0.32-$0.49-$0.79 - -$0.31+34.69%BeatN/A10N/ANov 5, 2020$17.79M
    Jun 30, 2020-$0.34$0.03-$0.81 - $1.64N/AN/AN/A10N/AAug 6, 2020$16.61M
    Mar 31, 2020$0.26-$0.51-$0.66 - $0.18+150.98%BeatN/A11N/AMay 7, 2020$49.59M
    Dec 31, 2019-$0.78-$0.47-$0.84 - -$0.19-65.96%MissN/A11N/AFeb 27, 2020N/A
    Sep 30, 2019-$0.52-$0.46-$0.88 - -$0.26-13.04%MissN/A10N/ANov 7, 2019$10.71M
    Jun 30, 2019-$0.64-$0.59-$0.81 - -$0.34-8.47%MissN/A11N/AAug 7, 2019$9.01M
    Mar 31, 2019-$0.31-$0.52-$0.70 - -$0.41+40.38%BeatN/A11N/AMay 9, 2019$29.48M
    Dec 31, 2018-$0.72-$0.48-$0.75 - -$0.22-50.00%Miss-2500.0%10N/AFeb 27, 2019$11.47M
    Sep 30, 2018-$0.53-$0.41-$0.67 - $0.00-29.27%MissN/A10N/ANov 6, 2018$12.51M
    Jun 30, 2018-$0.35-$0.42-$0.60 - $0.36+16.67%BeatN/A8N/AAug 8, 2018$21.34M
    Mar 31, 2018-$0.40-$0.56-$1.15 - -$0.04+28.57%BeatN/A8N/AMay 9, 2018$14.18M
    Dec 31, 2017$0.03-$0.46-$0.70 - -$0.25+106.52%BeatN/A8N/AMar 7, 2018$27.07M
    Sep 30, 2017-$0.28-$0.22-$0.36 - $0.07-27.27%MissN/A7N/ANov 7, 2017$24.14M
    Jun 30, 2017-$0.69-$0.33-$0.56 - -$0.18-109.09%MissN/A5N/AAug 7, 2017$8.75M
    Mar 31, 2017-$0.23-$0.51N/A+54.90%BeatN/AN/AN/AMay 5, 2017$11.65M
    Dec 31, 2016-$0.39-$0.42N/A+7.14%BeatN/AN/AN/AMar 2, 2017$6.27M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.04, after $0.39 the year before. It was -$1.62 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.04-110.6%
    Dec 31, 2024$0.39N/A
    Dec 31, 2023-$0.02N/A
    Dec 31, 2022-$1.52N/A
    Dec 31, 2021-$1.31N/A
    Dec 31, 2020-$0.72N/A
    Dec 31, 2019-$2.25N/A
    Dec 31, 2018-$2.00N/A
    Dec 31, 2017-$1.17N/A
    Dec 31, 2016-$1.62N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,51110
    2026Q1Mar 31, 20264,71610
    2025Q4Dec 31, 20257,56613
    2025Q3Sep 30, 20254,82610
    2025Q2Jun 30, 20254,26410
    2024Q4Dec 31, 20243,9938
    2024Q2Jun 30, 20243,5696

    2026Q3 Earnings Call

    Opening remarks

    Christopher W. Ogden CFO Thank you. Good afternoon, and thank you for joining us. Before we begin, I would like to remind everyone that during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC, at sec.gov. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. Earlier this afternoon, we filed our quarterly report on Form 10-Q for Q3 2026 and issued a press release with a summary of our third quarter 2026 financial results and business highlights. We encourage everyone to read today's filing and press release. Additionally, the recording of this call and our SEC filings can be found under the Investors and News section of our website. With me on the call today is Dr. Sean McCarthy, CytomX's Chief Executive Officer and Chairman. Sean will provide an update on our pipeline and company progress before I cover the financials for the quarter. We will then conclude with a Q&A session. With that, I will turn the call over to Sean.

    Sean A. McCarthy CEO and Chairman Thanks, Christopher, and good afternoon, everyone. We are very pleased to be here today to provide an update on our third quarter developments and what continues to be a highly productive year for CytomX as we advance our lead program, Varseta-M, toward its first potential registrational study in the first half of 2027. Varseta-M is an EpCAM-targeting topo-1 antibody-drug conjugate with strong potential in colorectal cancer and potentially other solid tumors. Importantly, to our knowledge, Varseta-M is first in class as the only EpCAM-directed ADC in clinical development. Varseta-M has been intentionally designed and uniquely enabled by our PROBODY platform, creating a significant opportunity for differentiation and long-term value creation. Strategically, we are initially developing Varseta-M in metastatic colorectal cancer as the lead indication. Our sense of urgency for Varseta-M is driven by the significant unmet need in colorectal cancer, which is the second-leading cause of cancer death in the United States and worldwide. Varseta-M is on the leading edge of ADC innovation in CRC and has the potential to be one of the first monotherapy ADCs to market for the treatment of this very challenging cancer type. In terms of commercial potential, there are an estimated 35,000 addressable patients in the United States with third-line or later CRC.

    Frequently Asked Questions About CTMX

    When is CytomX Therapeutics's next earnings date?

    CytomX Therapeutics's next earnings report is expected for Mar 15, 2027.

    Did CTMX beat earnings estimates last quarter?

    No. CytomX Therapeutics reported EPS of -$0.09 for the quarter ended Sep 30, 2026, below the -$0.07 estimate by 28.57%.

    What EPS do analysts expect from CTMX next quarter?

    The consensus EPS estimate for CytomX Therapeutics for the quarter ending Dec 31, 2026 is -$0.10 from 10 analysts, with estimates from -$0.12 to -$0.06.

    How often does CTMX beat earnings estimates?

    CytomX Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +31.28%.